Global Nucleic Acid Therapeutics Market Size study, by Product (Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi), RNA Aptamers), by Indication (Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, Others), by End-user (Hospitals

Global Nucleic Acid Therapeutics Market Size study, by Product (Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi), RNA Aptamers), by Indication (Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer, Others), by End-user (Hospitals, Physicians’ Offices, Others), and Regional Forecasts 2022-2032

The Global Nucleic Acid Therapeutics Market was valued at approximately USD 6.0 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 12.8% over the forecast period 2024-2032. Advancements in gene editing technologies, such as the CRISPR-Cas system, have transformed the therapeutic landscape, enabling precise genetic modifications and targeted correction of genetic mutations. This has spurred significant investments from both academic and commercial sectors, with these technologies expected to produce breakthrough medications and cures.

The introduction of synthetic oligonucleotides with precise chemical modifications has increased their stability and cellular uptake, addressing previous disadvantages like low stability and poor physicochemical properties. This enhancement has significantly boosted the therapeutic efficacy and safety profiles of these medicines, driving notable growth in the nucleic acid therapeutics market.

Advances in genetic research and biotechnology are propelling the market forward. Nucleic acid therapeutics, including antisense oligonucleotides (ASOs), RNA interference (RNAi), and RNA aptamers, offer targeted treatments for a range of genetic disorders, infectious diseases, and cancers. ASOs, with their strong therapeutic properties, dominate the market, effectively treating rare genetic disorders such as Duchenne muscular dystrophy and spinal muscular atrophy. RNAi medicines, known for their specificity in gene silencing, are also witnessing substantial growth, with successful drugs like patisiran and givosiran. RNA aptamers, though rare, show great potential due to their unique targeting capabilities.

The principal end-users of these medicines are hospitals, given their advanced diagnostic and therapeutic infrastructure. The market is expected to see significant growth due to ongoing innovations, increased prevalence of genetic disorders, and expanding applications in various medical fields.

The key regions considered in the study include Asia Pacific, North America, Europe, Latin America, and the Middle East and Africa . The North American region is both the leading and the fastest-growing region in the Nucleic Acid Therapeutics Market. This dominance is driven by several critical factors. Firstly, the region is home to a significant number of biotechnology and pharmaceutical companies actively engaged in the research, development, and commercialization of nucleic acid-based therapies. The strong presence of advanced research institutions and substantial investment in biotechnology further accelerate innovation in this field. Additionally, North America has a well-established regulatory framework that supports the approval and commercialization of cutting-edge therapies, fostering market growth. The region's robust healthcare infrastructure, coupled with increasing awareness and adoption of personalized medicine, also contributes to the expanding demand for nucleic acid therapeutics. Moreover, the availability of funding from both public and private sectors, along with strategic partnerships and collaborations, plays a crucial role in driving the rapid growth of this market in North America.

Major market players included in this report are:
Alynylam Pharmaceutials, Inc.
BioNTech
Ionis Pharmaceuticals, Inc.
Moderna
Nippon Shinyaku
Novartis
Pfizer
Sarepta Therapeutics
Biogen Inc.
Genzyme Sanofi
Percheron Therapeutics Ltd.
Thermo Fisher Scientific Inc.
Gilead Sciences, Inc.
Vertex Pharmaceuticals Incorporated

The detailed segments and sub-segment of the market are explained below:
By Product:
Anti-Sense Oligonucleotides (ASO)
RNA Interference (RNAi)
RNA Aptamers

By Indication:
Autoimmune Disorders
Infectious Diseases
Genetic Disorders
Cancer
Others

By End-user:
Hospitals
Physicians’ Offices
Others

By Region:
North America
U.S.
Canada

Europe
Germany
U.K.
France
Italy
Spain

Asia-Pacific
China
India
Japan
Australia
South Korea
Rest of Asia Pacific

Latin America
Brazil
Mexico
Rest of Latin America

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East and Africa

Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.